https://orcid.org/0000-0002-9048-4867
Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ovidiu Tirnavean, Christophe Van Bellinghen, Luc Monfort, Bruno Coulier, Michel Buche, Spiridon Papadatos, François Buche & Pierre-Yves Etienne. (2021) Inferior vena cava reconstruction with a superficial femoral vein graft after resection of a venous leiomyosarcoma. Acta Chirurgica Belgica 121:2, pages 144-151.
Read now
Read now
Maria A Smolle, Laurin Herbsthofer, Mark Goda, Barbara Granegger, Iva Brcic, Marko Bergovec, Susanne Scheipl, Barbara Prietl, Amin El-Heliebi, Martin Pichler, Armin Gerger, Florian Posch, Martina Tomberger, Pablo López-García, Julia Feichtinger, Claudia Baumgartner, Andreas Leithner, Bernadette Liegl-Atzwanger & Joanna Szkandera. (2021) Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. OncoImmunology 10:1.
Read now
Read now
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2020) Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology 9:1.
Read now
Read now
Sietse J Luk, Dirk M van der Steen, Renate S Hagedoorn, Ekaterina S Jordanova, Marco W Schilham, Judith VMG Bovée, Arjen HG Cleven, JH Frederik Falkenburg, Karoly Szuhai & Mirjam HM Heemskerk. (2018) PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. OncoImmunology 7:12.
Read now
Read now
Articles from other publishers (29)
Divita Pandita, Mrugakshi Dave & Brian Schulte. (2023) PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates. BMJ Case Reports 16:11, pages e256697.
Crossref
Crossref
Matthieu Roulleaux-Dugage & Antoine Italiano. (2023) New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Sho Watanabe, Tatsunori Shimoi, Tadaaki Nishikawa, Asuka Kawachi, Hitomi Sumiyoshi Okuma, Momoko Tokura, Shu Yazaki, Chiharu Mizoguchi, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Yuki Kojima, Kazuki Sudo, Emi Noguchi, Akihiko Yoshida, Akira Kawai, Yasuhiro Fujiwara & Kan Yonemori. (2023) Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy. Scientific Reports 13:1.
Crossref
Crossref
Sarah Watson, Nadege Gruel & François Le Loarer. (2023) New developments in the pathology and molecular biology of retroperitoneal sarcomas. European Journal of Surgical Oncology 49:6, pages 1053-1060.
Crossref
Crossref
Brandon M. Cope, Raymond S. Traweek, Rossana Lazcano, Emily Z. Keung, Alexander J. Lazar, Christina L. Roland & Elise F. Nassif. (2023) Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers 15:7, pages 2099.
Crossref
Crossref
Ninna Aggerholm-Pedersen, Henriette Nymark Friis, Thomas Baad-Hansen, Holger Jon Møller & Birgitte Sandfeld-Paulsen. (2023) Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients. Cancers 15:5, pages 1544.
Crossref
Crossref
Alicia A. Gingrich, Elise F. Nassif, Christina L. Roland & Emily Z. Keung. (2023) The Landscape of Immunotherapy for Retroperitoneal Sarcoma. Current Oncology 30:2, pages 2144-2158.
Crossref
Crossref
Minchao Lv, Feixiong He, Jinku Guo, Zhenxin Zheng, Wei Wang & Jun Xie. (2022) Identification of hub genes correlated with tumor-associated M1-like macrophage infiltration in soft tissue sarcomas. Frontiers in Genetics 13.
Crossref
Crossref
Mei-Ling Chen, Li Fan, Guang-Rong Huang & Zhi-Feng Sun. (2022) lncRNA EGFR-AS1 facilitates leiomyosarcoma progression and immune escape via the EGFR–MYC–PD-L1 axis. International Immunology 34:7, pages 365-377.
Crossref
Crossref
Guojun Liu, Mikhail A. Bolkov, Khyber Shinwari, Irina A. Tuzankina & Valery A. Chereshnev. Prognostic and immunotherapeutic significance of tumor- infiltrating M2 macrophages in muscle-invasive bladder cancer. Prognostic and immunotherapeutic significance of tumor- infiltrating M2 macrophages in muscle-invasive bladder cancer.
Suk Wai Lam, Marie Kostine, Noel F C C de Miranda, Patrick Schöffski, Che‐Jui Lee, Hans Morreau & Judith V M G Bovée. (2021) Mismatch repair deficiency is rare in bone and soft tissue tumors. Histopathology 79:4, pages 509-520.
Crossref
Crossref
Tong Wu, Ying-Cheng Yang, Bo Zheng, Xue-Bing Shi, Wei Li, Wen-Cong Ma, Shan Wang, Zhi-Xuan Li, Yan-Jing Zhu, Jian-Min Wu, Kai-Ting Wang, Yan Zhao, Rui Wu, Cheng-Jun Sui, Si-Yun Shen, Xuan Wu, Lei Chen, Zhen-Gang Yuan & Hong-Yang Wang. (2021) Distinct Immune Signatures in Peripheral Blood Predict Chemosensitivity in Intrahepatic Cholangiocarcinoma Patients. Engineering 7:10, pages 1381-1392.
Crossref
Crossref
Siddh van Oost, Debora M. Meijer, Marieke L. Kuijjer, Judith V. M. G. Bovée & Noel F. C. C. de Miranda. (2021) Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. Biomedicines 9:8, pages 1048.
Crossref
Crossref
Luana Madalena Sousa, Jani Sofia Almeida, Tânia Fortes-Andrade, Manuel Santos-Rosa, Paulo Freitas-Tavares, José Manuel Casanova & Paulo Rodrigues-Santos. (2021) Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy. Cancers 13:15, pages 3885.
Crossref
Crossref
Larisa LehmerFranchesca ChoiChristina KrausJessica ShiuSebastien de Feraudy & Ashley Elsensohn. (2021) Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review. The American Journal of Dermatopathology 43:5, pages 321-330.
Crossref
Crossref
Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts, Diether Lambrechts & Frédéric Amant. (2021) Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers 13:9, pages 2040.
Crossref
Crossref
Ali Mohammed Refaat Ali, Jen-Wei Tsai, Cheuk Hong Leung, Heather Lin, Vinod Ravi, Anthony P. Conley, Alexander J. Lazar, Wei-Lien Wang & Michael J. Nathenson. (2020) The immune microenvironment of uterine adenosarcomas. Clinical Sarcoma Research 10:1.
Crossref
Crossref
Feng Wang, Tao Yu, Chengbin Ma, Hongmou Yuan, Haifei Zhang & Zhiyu Zhang. (2020) Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients. Frontiers in Oncology 10.
Crossref
Crossref
Vanina E. Wainsztein & Tom W. Chen. (2020) When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. Journal of Immunotherapy and Precision Oncology 3:2, pages 69-82.
Crossref
Crossref
Iseulys Richert, Anne Gomez-Brouchet, Corinne Bouvier, Gonzague Du Bouexic De Pinieux, Marie Karanian, Jean-Yves Blay & Aurélie Dutour. (2020) The immune landscape of chondrosarcoma - potential for therapeutic targeting of CSFR1+ macrophages. Journal of Bone Oncology 20, pages 100271.
Crossref
Crossref
Keith M. Skubitz, Jon D. Wilson, Edward Y. Cheng, Bruce R. Lindgren, Kristin L. M. Boylan & Amy P. N. Skubitz. (2019) Effect of chemotherapy on cancer stem cells and tumor-associated macrophages in a prospective study of preoperative chemotherapy in soft tissue sarcoma. Journal of Translational Medicine 17:1.
Crossref
Crossref
V. Е. Bugaev, M. P. Nikulin, N. I. Pospekhova, V. M. Safronova, N. V. Kokosadze, Ya. A. Bozhchenko, S. N. Nered, L. N. Lyubchenko & I. S. Stilidi. (2019) Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas. Advances in molecular oncology 6:3, pages 37-48.
Crossref
Crossref
Fei Yu, Lei Gong, Zheng Mo, Wenran Wang, Meilong Wu, Jianghui Yang, Qiongqiong Zhang, Li Li, Jingjing Yao & Jiahong Dong. (2019) Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. BioScience Trends 13:1, pages 58-69.
Crossref
Crossref
Diane Evrard, Petr Szturz, Annemilaï Tijeras-Raballand, Lucile Astorgues-Xerri, Chloé Abitbol, Valérie Paradis, Eric Raymond, Sébastien Albert, Béatrix Barry & Sandrine Faivre. (2019) Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy. Oral Oncology 88, pages 29-38.
Crossref
Crossref
Sander Bekeschus, Christian Seebauer, Kristian Wende & Anke Schmidt. (2018) Physical plasma and leukocytes – immune or reactive?. Biological Chemistry 400:1, pages 63-75.
Crossref
Crossref
Alisa B. Lee-Sherick, Kristen M. Jacobsen, Curtis J. Henry, Madeline G. Huey, Rebecca E. Parker, Lauren S. Page, Amanda A. Hill, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Craig T. Jordan, Deborah DeRyckere & Douglas K. Graham. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:21.
Crossref
Crossref
Matthew A. Ingham, Julia E. McGuinness, Kevin Kalinsky & Gary K. Schwartz. (2018)
Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous
BRCA2
Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents
. JCO Precision Oncology:2, pages 1-6.
Crossref
Crossref
Santhosh Kalash Rajendrakumar, Saji Uthaman, Chong-Su Cho & In-Kyu Park. (2018) Nanoparticle-Based Phototriggered Cancer Immunotherapy and Its Domino Effect in the Tumor Microenvironment. Biomacromolecules 19:6, pages 1869-1887.
Crossref
Crossref
Daniela KatzEmanuela PalmeriniSeth M. Pollack. (2018) More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments. American Society of Clinical Oncology Educational Book:38, pages 925-938.
Crossref
Crossref